SpO2 (Peripheral Oxygen Saturation) Measurement ValidationSpO2 PedsNCT07615738
SpO2 Infant and Pediatric Study
A study testing SpO2 Sensor in people with SpO2 (Peripheral Oxygen Saturation) Measurement Validation and SpO2, run by GE Healthcare at 1 site in United States.
Trial summary
This study evaluates the pulse oximetry (SpO₂) sensor for clinical performance, form, and fit in hospitalized infants and children (28 days to 12 years). It compares SpO₂ measurements from the device to arterial oxygen saturation (SaO₂) values from arterial CO-oximetry, and assesses the reliability of usable data… Read more about this study
- Who is it for?
- Ages 29 days to 12 years
- Conditions the study is for
- SpO2 (Peripheral Oxygen Saturation) Measurement Validation, SpO2
- What is being tested?
- SpO2 Sensor
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jun 2026to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 29 days to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- subjects are 1-23 months (infant cohort) or 2-12 years old (child cohort)
- requiring arterial blood samples per the site's standard of care.
Who cannot join
- Fractional Methemoglobinemia (FMetHb >2%) or Fractional carboxyhemoglobinemia (FCOHb >3%), within 24 hours of arterial blood draw.
- Severe anemia (tHb <7g/dL) within 4 hours prior to arterial blood gas draw.
- Hematocrit (Hct) <25 within 4 hours prior to arterial blood gas draw.
- Patients with injuries, deformities, or abnormalities which may prevent proper application of the sensor.
- Patients on Extracorporeal Membrane Oxygenation (ECMO).
- Patients receiving point of care (POC) testing for blood gases.
Show all 11Show fewer
- Patients with diseases/conditions that may cause differential (or reverse differential) cyanosis including, but not limited to:
- Patent ductus arteriosus with pulmonary arterial hypertension.
- Pulmonary hypertension and left-heart abnormalities aortic arch hypoplasia, interrupted aortic arch, critical coarctation, and critical aortic stenosis.
- Children with transposition of the great arteries (TGA) and coarctation of the aorta or interrupted aortic arch, and TGA with suprasystemic pulmonary vascular resistance.
- At the discretion of the principal investigator or designee due to the subject health condition.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Nebraska Medical Center Children's Hospital
Omaha, Nebraska, 68114
Michael Facciolo, MD, 402-671-6325, mfacciolo@childrensnebraska.org
Michael Facciolo, MD
About this study
Official title: Assessment of TruSignal SpO2 Form, Fit and Clinical Performance With Infant and Child Patients
This study evaluates the pulse oximetry (SpO₂) sensor for clinical performance, form, and fit in hospitalized infants and children (28 days to 12 years). It compares SpO₂ measurements from the device to arterial oxygen saturation (SaO₂) values from arterial CO-oximetry, and assesses the reliability of usable data, performance across skin tones, and user feedback.
Read the detailed description
This prospective clinical study evaluates a pulse oximetry sensor in hospitalized infants (28 days to 23 months) and children (2-12 years) under routine clinical conditions. The primary objective is to assess the accuracy and agreement of SpO₂ measurements compared with reference SaO₂ values obtained from CO-oximetry analysis of simultaneously drawn arterial blood, using methods aligned with ISO 80601-2-61: 2026 3rd edition published in April 2026.
Secondary objectives include measuring the proportion of time the device produces invalid or unusable data to assess reliability for clinical use. The safety objective is to collect safety information, including type and number of AEs, SAEs, and device issues. Results may support product development, regulatory submissions, and marketing activities.
- Being tested
- SpO2 Sensor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SpO2 SensorDevice
SpO2 sensors use red and infrared LED light to estimate the arterial oxygen saturation.
| Study group | Role | What they receive |
|---|---|---|
| All Subjects | Experimental | Participants participating in this study will be connected to SpO2 sensors. SpO2 data will be independently collected from each sensor and paired with simultaneous arterial blood sample SaO₂ values. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard. Receives: Device: SpO2 Sensor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Collection of SpO2 Percentage Sensor Data with simultaneous SaO2 values
The collection of SpO2 percentage sensor data with simultaneous SaO2 values percentage from each subject enrolled in the study.
Measured: From enrollment to the end of standard of care arterial cannulation, approximately 1 week.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2026
- Study start15 Jun 2026 (estimated)
- Primary completion31 May 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for SpO2 (Peripheral Oxygen Saturation) Measurement ValidationStudies of the same condition, open and under way.
- More trials run by GE HealthcareThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- GE Healthcare
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07615738
- Sponsor's protocol ID
- SA-000192
- Acronym
- SpO2 Peds
- Status last verified
- May 2026
- First submitted
- 18 May 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571-82. doi: 10.1080/10543400701329422.
PubMed 17613642Ruppel H, Makeneni S, Faerber JA, Lane-Fall MB, Foglia EE, O'Byrne ML, Bonafide CP. Evaluating the Accuracy of Pulse Oximetry in Children According to Race. JAMA Pediatr. 2023 May 1;177(5):540-543. doi: 10.1001/jamapediatrics.2023.0071.
PubMed 36939727Okunlola OE, Lipnick MS, Batchelder PB, Bernstein M, Feiner JR, Bickler PE. Pulse Oximeter Performance, Racial Inequity, and the Work Ahead. Respir Care. 2022 Feb;67(2):252-257. doi: 10.4187/respcare.09795. Epub 2021 Nov 12.
PubMed 34772785Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology. 2005 Apr;102(4):715-9. doi: 10.1097/00000542-200504000-00004.
PubMed 15791098
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of TruSignal SpO2 Form, Fit and Clinical Performance With Infant and Child Patients
- ClinicalTrials.gov ID
- NCT07615738
- Acronym / sponsor ID
- SpO2 Peds / SA-000192
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- GE HealthcareIndustry (pharma, biotech, devices)
- Study start
- 15 Jun 2026 (estimated)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 29 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the pulse oximetry (SpO₂) sensor for clinical performance, form, and fit in hospitalized infants and children (28 days to 12 years). It compares SpO₂ measurements from the device to arterial oxygen saturation (SaO₂) values from arterial CO-oximetry, and assesses the reliability of usable data, performance across skin tones, and user feedback.
Detailed description
This prospective clinical study evaluates a pulse oximetry sensor in hospitalized infants (28 days to 23 months) and children (2-12 years) under routine clinical conditions. The primary objective is to assess the accuracy and agreement of SpO₂ measurements compared with reference SaO₂ values obtained from CO-oximetry analysis of simultaneously drawn arterial blood, using methods aligned with ISO 80601-2-61: 2026 3rd edition published in April 2026.
Secondary objectives include measuring the proportion of time the device produces invalid or unusable data to assess reliability for clinical use. The safety objective is to collect safety information, including type and number of AEs, SAEs, and device issues. Results may support product development, regulatory submissions, and marketing activities.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All Subjects | Experimental | Device: SpO2 SensorParticipants participating in this study will be connected to SpO2 sensors. SpO2 data will be independently collected from each sensor and paired with simultaneous arterial blood sample SaO₂ values. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard. |
Who may qualify
- Ages
- 29 days to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- subjects are 1-23 months (infant cohort) or 2-12 years old (child cohort)
- requiring arterial blood samples per the site's standard of care.
Key exclusion criteria (11 listed)
- Fractional Methemoglobinemia (FMetHb >2%) or Fractional carboxyhemoglobinemia (FCOHb >3%), within 24 hours of arterial blood draw.
- Severe anemia (tHb <7g/dL) within 4 hours prior to arterial blood gas draw.
- Hematocrit (Hct) <25 within 4 hours prior to arterial blood gas draw.
- Patients with injuries, deformities, or abnormalities which may prevent proper application of the sensor.
- Patients on Extracorporeal Membrane Oxygenation (ECMO).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SpO2 SensorSpO2 sensors use red and infrared LED light to estimate the arterial oxygen saturation. | Device | All Subjects |
Primary outcome
Collection of SpO2 Percentage Sensor Data with simultaneous SaO2 values
Time frame: From enrollment to the end of standard of care arterial cannulation, approximately 1 week.
The collection of SpO2 percentage sensor data with simultaneous SaO2 values percentage from each subject enrolled in the study.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Background: PubMed 17613642Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571-82. doi: 10.1080/10543400701329422.
- Background: PubMed 36939727Ruppel H, Makeneni S, Faerber JA, Lane-Fall MB, Foglia EE, O'Byrne ML, Bonafide CP. Evaluating the Accuracy of Pulse Oximetry in Children According to Race. JAMA Pediatr. 2023 May 1;177(5):540-543. doi: 10.1001/jamapediatrics.2023.0071.
- Background: PubMed 34772785Okunlola OE, Lipnick MS, Batchelder PB, Bernstein M, Feiner JR, Bickler PE. Pulse Oximeter Performance, Racial Inequity, and the Work Ahead. Respir Care. 2022 Feb;67(2):252-257. doi: 10.4187/respcare.09795. Epub 2021 Nov 12.
- Background: PubMed 15791098Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology. 2005 Apr;102(4):715-9. doi: 10.1097/00000542-200504000-00004.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
University of Nebraska Medical Center Children's Hospital
Omaha, United States
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SpO2 Sensor in people with SpO2 (Peripheral Oxygen Saturation) Measurement Validation and SpO2, run by GE Healthcare at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Collection of SpO2 Percentage Sensor Data with simultaneous SaO2 values (time frame: From enrollment to the end of standard of care arterial cannulation, approximately 1 week.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07615738, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.